Episodes (Page 10)
✨
Richard Pazdur's retirement from the US FDA.
Derrick Gingery
Michael McCaughan
Nielsen Hobbs
Sue Sutter
✨
Novel intranasal H5 flu vaccine development.
✨
Regeneron navigates success and patent expirations.
✨
Regeneron's balance of success and patent expiry.
25m
✨
Latest developments in dry age-related macular degeneration (dry AMD).
✨
State of rare disease R&D and genomics.
Matthew Wood
✨
Review of biopharma dealmaking in 2025.
Joseph Haas
Roel Van den Akker
✨
Key outcomes from the American Society of Hematology (ASH) meeting.
✨
ASH meeting highlights: Jaypirca for front-line therapy.
✨
Trump's UK drug pricing negotiation success.
✨
Trump wins UK drug pricing negotiations.
✨
Tackling drug resistance in oncology with Kairos Pharma.
Neil Bhowmick
✨
Breakdown of the US FDA's CDER leadership changes.
Richard Pazdur
Tracy Beth Hoeg
✨
Five key themes in China's biopharma growth for 2025.
✨
Medicare price cuts likely smaller than CMS estimates.
✨
2027 Medicare price cuts may be smaller than expected.
✨
Scrip reports on Jefferies Global Healthcare Conference in London.
✨
New obesity treatments beyond GLP-1s are emerging.
✨
Obesity treatments beyond GLP-1s are discussed.